quinta-feira, 12 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 15, 2026

Stocks Boosted by Chip Demand Optimism

View original at nasdaq.com
Stocks Boosted by Chip Demand Optimism The S&P 500 Index ($SPX) (SPY) on Thursday closed up +0.26%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.60%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.32%…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q1 sales forecast stronger than expected

    80% confidence
  • Has been assured that Iran would stop killing protesters, signaling the US could hold off on a threatened military response

    80% confidence
  • Baker Hughes has the largest installed base of rotating and artificial lift equipment in Venezuela

    80% confidence
  • Sees providing power generation equipment for crude production in Venezuela as biggest immediate growth opportunity

    80% confidence
  • S&P earnings growth is expected to climb by +8.4% in Q4

    80% confidence
  • Has no plans to fire Fed Chair Powell despite a Justice Department probe into the central bank's renovation

    80% confidence
  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings are expected to increase by +4.6%

    80% confidence
  • 2026 capital expenditure forecast increased to $52 billion-$56 billion from $40.9 billion in 2025

    80% confidence
  • The Fed needs to stay restrictive because he expects inflation pressures to continue through 2026

    80% confidence
  • With inflation pressures still evident, my preferences would be to keep monetary policy modestly restrictive

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,565 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Stocks Boosted by Chip Demand Optimism — Source | Via News | pt.VIA.NEWS